On July 8, 2022 GlyTherix reported that it has commenced an exciting new collaboration with the GastroEsophageal Malignancies Investigator Network Initiative (GEMINI) to test its Miltuximab monoclonal antibody therapies in gastroesophageal cancers (Press release, Glytherix, JUL 8, 2022, View Source [SID1234616534]). GEMINI, backed by the Torrey Coast Foundation, is a multi-institution collaboration of 22 scientific and clinical investigators dedicated to developing innovative new strategies to treat gastroesophageal malignancies.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Dr Sandra Ryeom, Associate Professor in the Division of Surgical Sciences in the Department of Surgery at Columbia University Irving Medical Center and the Scientific Director of GEMINI said, "GEMINI was created to accelerate the clinical trials of new therapies for gastroesophageal malignancies. We have established a network of preclinical and clinical investigators, with expertise in pre-clinical drug screening using in vitro and in vivo models, together with clinical investigators who have led Phase I clinical trials using targeted therapies in combination with immunotherapy and chemotherapy. We have exciting early data about GPC-1 expression in gastroesophageal malignancies and we look forward to testing GlyTherix’s therapies in our models".
Dr Brad Walsh said "GEMINI is an outstanding example of scientific and clinical collaboration to accelerate novel treatments into the clinic. Our Miltuximab therapy has proven safe in our First-in-Human clinical trial and we are looking forward to establishing its efficacy in the treatment of solid tumors. Gastroesophageal cancer is a significant unmet need and we hope that the preclinical data we obtain from this collaboration will provide the data to progress Miltuximab into clinical trials for these patients".